Prurigo of Pregnancy (PP) is a pruritic dermatosis characterized by intensely itchy papulonodules, typically affecting the extensor surfaces of the extremities and the dorsal aspects of the hands and feet. Despite being relatively common, PP remains insufficiently studied. This review aims to describe its clinical presentation and management, and to summarize the available evidence regarding treatment effectiveness. This systematic review followed PRISMA guidelines. Searches of PubMed, EMBASE, Web of Science, and Cochrane databases were conducted from inception to 13 August 2024. Eligible studies included randomized controlled trials, cohort studies, case-control studies, crosssectional studies, case series, and case reports that reported PP clinical features or treatments and were written in English. Exclusion criteria included failure to meet inclusion parameters, high risk of bias, or poor quality. Methodological assessment was performed using the Newcastle- Ottawa Scale and the synthesis of non-randomized studies approach. Four studies encompassing sixty-three patients were included. PP commonly presented with pruritic papulonodular eruptions distributed across the extremities, back, or buttocks, with variable onset during pregnancy. Several associated conditions were noted, including a history of dermatologic disorders such as intrahepatic cholestasis of pregnancy and systemic conditions such as anemia and obesity. Reported treatments varied widely and included topical corticosteroids, emollients, oral antihistamines, systemic corticosteroids, and narrowband UVB phototherapy. Therapeutic response also varied: some patients improved before delivery, while others continued to experience symptoms for several months postpartum. This review highlights the heterogeneity of PP in clinical features, associated conditions, and therapeutic outcomes. The variability in presentation and response underscores the need for standardized diagnostic criteria and treatment protocols. Larger, methodologically rigorous studies using consistent outcome measures are needed to better characterize PP, identify predictors of treatment success, and guide evidence-based management strategies. Such research will ultimately improve patient care and enable more precise, effective, and individualized treatment recommendations in practice.

Dana Hendie is undergoing completing her postgraduate studies in Mohammed Bin Rashid University of Medicine and Health Sciences. She has multiple articles, published in journals such as Oxford Medical Case Reports. She has also presented her research in multiple conferences such as RCOG world conference and the Dubai Health conference.